Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a buy rating to a hold rating in a research note published on Saturday morning.

Other equities research analysts have also recently issued research reports about the stock. Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday. Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS:BAYRY traded down $0.16 during trading on Friday, hitting $7.87. The company's stock had a trading volume of 385,705 shares, compared to its average volume of 807,125. The company has a 50-day moving average of $6.67 and a 200-day moving average of $5.96. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $8.58. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.32 and a quick ratio of 0.81. The firm has a market cap of $30.93 billion, a price-to-earnings ratio of -30.27 and a beta of 0.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. On average, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were issued a dividend of $0.0224 per share. This is a positive change from Bayer Aktiengesellschaft's previous dividend of $0.02. This represents a yield of 0.38%. The ex-dividend date was Tuesday, April 29th. Bayer Aktiengesellschaft's dividend payout ratio (DPR) is -2.17%.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.